Morphic Therapeutic’s Post

Biotech deals continue in 2024 with today’s acquisition announcement from Lilly and Morphic Therapeutic. 📈 Morphic Therapeutic is developing a new generation of oral integrin therapies for the treatment of serious chronic diseases. 💊 Their focus is integrin proteins, which function in cell-cell and cell-extracellular matrix interactions. Integrins have vast therapeutic potential, having been implicated in autoimmune disorders, fibrosis, and cancer. One of Morphic's leading programs is MORF-057, which is being developed for the treatment of IBD, including ulcerative colitis and Crohn's disease. In addition to MORF-057, Morphic's pipeline includes candidates targeting other integrins, aimed at treating conditions like myelofibrosis, solid tumors, and pulmonary arterial hypertension. How else might Morphic Therapeutic's integrin work dovetail with Lilly’s portfolio of therapeutics? Let me know in the comments 👇 https://lnkd.in/e5Kqvf-F

👉  A New Era for Patient Recruitment and Retention in Rare Disease Norstella #pharmaceuticals #biopharma #raredisease #patientrecruitment #clinicaloperations #drugdevelopment #clinicaltrials #pharmapipeline #therapeuticarea #lifesciences

#News: AbbVie has announced that it will be expanding its inflammatory and autoimmune disease portfolio by acquiring Landos Biopharma, Inc. for up to $212.5m. #Landos is a #clinicalstage #biopharmaceutical company that focuses on the development of #oraltherapeutics for patients with #autoimmunediseases. Inflammatory conditions such as #inflammatoryboweldisease (IBD) cause excess inflammation, while the body’s natural defence system mistakenly attacks normal cells as opposed to foreign cells in autoimmune diseases. In some conditions, including #rheumatoidarthritis and #lupus, both autoimmune and inflammatory diseases play a role when #antibodies get directed against the body’s own cells, causing inflammation. Under the terms of the agreement, #AbbVie will acquire Landos for approximately $137.5m, plus an additional $75m, subject to its achievement of a clinical development milestone. Meanwhile, AbbVie will gain rights to advance the clinical development of Landos’ lead investigational asset, NX-13, as a potential treatment for patients living with #ulcerativecolitis (UC) and #Crohnsdisease, two forms of IBD. Read more from PM LIVE 👇🏼 https://lnkd.in/gjEG_DW4

Amgen’s $27.8 B acquisition of Horizon Therapeutics included Uplizna, a key asset now showing promise for label expansion. In the Phase 3 MITIGATE study, Uplizna reduced the risk of disease flare in immunoglobulin G4-related disease (IgG4-RD) by 87% over 52 weeks. The study met secondary endpoints, indicating reduced flares and disease remission, with no new safety signals. This marks the first placebo-controlled trial supporting a steroid-sparing regimen for IgG4-RD. Regulatory filings in the US and other "key markets" are in the planning. Originally approved in 2020 for neuromyelitis optica spectrum disorder, Uplizna could be a significant growth driver for Amgen. Detailed News: https://lnkd.in/gYmbntaP Stay updated on the latest trends and news in the pharmaceutical industry. Follow our page for more insights: https://lnkd.in/de5zNWmK #Amgen #HorizonTherapeutics #Uplizna #IgG4RD #BiotechNews #ClinicalTrialSuccess #Trending #RASLSS

Boehringer Ingelheim is setting an ambitious course with plans to launch 25 new treatments by 2030, despite challenges with Cyltezo. This pivot to their late-stage pipeline, including significant advancements in treatments for rare cancers and liver diseases, highlights a robust commitment to innovation. Their strategy raises critical questions: ▪️ How will Boehringer integrate such a significant number of new treatments effectively? ▪️ What impact will this have on the broader healthcare landscape? #HealthcareInnovation #Pharmaceuticals #StrategicPlanning

Latest Healthcare News & Updates: Bristol Myers Squibb and Exelixis's Opdivo in Combination with CABOMETYX Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma. AstraZeneca's AIRSUPRA Now Available as the First and Only FDA-approved Anti-inflammatory Rescue Option for Asthma. GC Biopharma (GC녹십자)’s Sanfilippo Syndrome (Type A) Treatment Received Orphan Drug Designation (ODD) From the European Medicines Agency (EMA). NRx Pharmaceuticals, Inc. Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections. Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Progressive Multiple Sclerosis AstraZeneca’s Voydeya Receives First-ever Regulatory Approval in Japan for Adults with PNH. Get a more detailed analysis, at: https://lnkd.in/gJjb-XU3 #lifesciences #pharmaceuticals #marketresearch #marketanalysis #healthcare #markettrends #health #medical #news #healthcarenews #pharmanews #clinicaltrials #clinicalresearch

AbbVie Inc. has announced its acquisition of Landos Biopharma, Inc., a clinical stage biopharmaceutical company specializing in developing novel, oral therapeutics for autoimmune diseases. This acquisition is expected to advance the clinical development of Landos' lead investigational asset, NX-13, a first-in-class, oral NLRX1 agonist with a bimodal mechanism of action. NLRX1 is known to regulate immunometabolism and inflammation, impacting multiple mechanisms of inflammatory bowel disease (IBD) pathogenesis. NX-13 is currently being evaluated in a Phase 2 clinical trial for ulcerative colitis (UC), with promising potential for the treatment of UC and Crohn's disease. AbbVie's acquisition of Landos represents a significant step forward in addressing the therapeutic gap in current treatment options for autoimmune diseases. By leveraging AbbVie's expertise in global development and therapeutic area leadership, NX-13 could potentially provide a novel and effective approach to treating UC and Crohn's disease, ultimately benefiting patients worldwide Source : https://lnkd.in/e8DPfXpq #AbbVie #LandosBiopharma #AutoimmuneDiseases #NX13 #UlcerativeColitis #CrohnsDisease #ClinicalTrial #InnovationInHealthcare #HealthcareAdvancements #Immunometabolism #InflammatoryBowelDisease #IBDResearch #Biopharmaceuticals #HealthcareInnovation #GlobalHealthcare #PatientCare #TherapeuticAdvances #ClinicalDevelopment #HealthcareNews

What progress has LeviCure Ltd. made in advancing its #𝗕𝗿𝗲𝗮𝗸𝘁𝗿𝗼𝘂𝗴𝗵 treatment to reverse 𝗧𝘆𝗽𝗲 𝟭 𝗗𝗶𝗮𝗯𝗲𝘁𝗲𝘀 (#𝗧𝟭𝗗)? LeviCure Ltd. is a clinical-stage pharmaceutical startup focused on providing breakthrough treatment for Type 1 Diabetes (T1D) patients worldwide to facilitate 𝗳𝘂𝗹𝗹 𝗿𝗲𝗺𝗶𝘀𝘀𝗶𝗼𝗻. Our disruptive patent-protected treatment combines a novel, proprietary extended-release gastro-retentive formulation of GABA, a DPP-4i, and a PPI to 𝗿𝗲𝘀𝘁𝗼𝗿𝗲 the insulin-secretory function of 𝗽𝗮𝗻𝗰𝗿𝗲𝗮𝘁𝗶𝗰 𝗶𝘀𝗹𝗲𝘁 β-𝗰𝗲𝗹𝗹𝘀, aiming to achieve complete insulin independence and long-term remission in recent-onset T1D patients and provide better glycemic control for patients with residual β-cell function. 𝗦𝘁𝗮𝘁𝘂𝘀 𝗮𝗻𝗱 𝗔𝗰𝗵𝗶𝗲𝘃𝗲𝗺𝗲𝗻𝘁𝘀: •           Levicure has published a proof-of-concept study in collaboration with Uppsala University and Assuta Medical Centers, demonstrating promising results in recent-onset T1D patients, with 𝟳𝟬% 𝗮𝗰𝗵𝗶𝗲𝘃𝗶𝗻𝗴 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲 𝗶𝗻𝘀𝘂𝗹𝗶𝗻 𝗱𝗶𝘀𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗮𝘁𝗶𝗼𝗻. (https://lnkd.in/eu5z9fsR) •           NOD mice studies have further validated the 𝗲𝗳𝗳𝗶𝗰𝗮𝗰𝘆 of our treatment. (https://lnkd.in/dgj5i9Ut) •           The detailed 𝗠𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺 𝗼𝗳 𝗔𝗰𝘁𝗶𝗼𝗻 of our combination treatment has been submitted for publication in a high-impact journal (available on request) •           The company has been 𝗴𝗿𝗮𝗻𝘁𝗲𝗱 patents for the triple combination in the EU and USA and is pursuing additional patents for a quadruple therapy and as a platform to treat additional indications (Multiple sclerosis, Alzheimer’s disease, Parkinson's disease ) •           The company submitted a provisional patent application for an 𝗲𝘅𝘁𝗲𝗻𝗱𝗲𝗱-𝗿𝗲𝗹𝗲𝗮𝘀𝗲 𝗴𝗮𝘀𝘁𝗿𝗼-𝗿𝗲𝘁𝗲𝗻𝘁𝗶𝘃𝗲 𝗚𝗔𝗕𝗔 𝗰𝗼𝗺𝗽𝗼𝘀𝗶𝘁𝗶𝗼𝗻. This superior pharmaceutical offering will maximise GABA bioavailability, ensure once-daily delivery, and maintain more consistent plasma concentrations for optimal effect at a lower overall dosage. •           Levicure received positive feedback from the FDA during a 𝗽𝗿𝗲-𝗜𝗡𝗗 𝗺𝗲𝗲𝘁𝗶𝗻𝗴, paving the way for a 𝗣𝗵𝗮𝘀𝗲 𝟮 clinical trial and indicating the potential for accelerated development and review. •           The combination treatment is eligible for multiple 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗮𝗻𝗱 𝗺𝗮𝗿𝗸𝗲𝘁 𝗲𝘅𝗰𝗹𝘂𝘀𝗶𝘃𝗶𝘁𝗶𝗲𝘀, providing significant protection on top of our IP portfolio. Stay tuned. We will be happy to answer your questions and discuss our future plans during the webinar scheduled on the 17th of July (https://lnkd.in/dHB-zVZx). We invite your thoughts, insights, and discussions as we continue this journey together! #T1D #Type1Diabetes #Healthcare #Breaktrough #DiabetesCare

What’s New: Advancements in Sickle Cell Disease Therapies Delve into the latest advancements in Sickle Cell Disease therapies with DelveInsight's comprehensive report. Covering FDA, EMA, and PDMA approvals, clinical trials, mechanisms, and key companies like Bellicum Pharmaceuticals, Novartis, Novo Nordisk, and Vertex Pharmaceuticals, the report explores over 50 therapies in various stages of development. From emerging treatments like BPX-501 T cells to insights on Mozobil, the report provides a detailed overview. Addressing the critical shortage of technicians, the VP of Training at Repairify emphasizes the importance of strategic realignments and sustainable growth in the auto repair industry. Explore the evolving landscape of Sickle Cell Disease treatment, including leading companies and pipeline therapies such as Canakinumab and CTX001. With accreditation for training programs, Repairify aims to contribute significantly to addressing the challenges in the automotive repair industry, offering more opportunities for top-notch training to future technicians. Read more: https://lnkd.in/eCy88tA5 #SickleCellDisease #HealthcareInnovation #MedicalAdvancements #HealthTechUpdates #MedicalBreakthroughs #FutureOfMedicine #SickleCellAwareness #InnovativeTherapies #MedicalResearch

Fresenius Kabi, a subsidiary of Fresenius SE, has announced the availability of Tyenne®, the first tocilizumab biosimilar in the U.S. This biosimilar, 𝗮𝗽𝗽𝗿𝗼𝘃𝗲𝗱 𝗯𝘆 𝘁𝗵𝗲 𝗙𝗗𝗔 𝗳𝗼𝗿 𝗯𝗼𝘁𝗵 𝗶𝗻𝘁𝗿𝗮𝘃𝗲𝗻𝗼𝘂𝘀 𝗮𝗻𝗱 𝘀𝘂𝗯𝗰𝘂𝘁𝗮𝗻𝗲𝗼𝘂𝘀 𝘂𝘀𝗲, offers a more accessible and affordable treatment option for patients with chronic autoimmune diseases. Tyenne®'s launch contributes significantly to Fresenius' (Bio)Pharma platform, aligning with its #FutureFresenius strategy. 𝗧𝘆𝗲𝗻𝗻𝗲® 𝗺𝗮𝗿𝗸𝘀 𝗙𝗿𝗲𝘀𝗲𝗻𝗶𝘂𝘀' 𝘁𝗵𝗶𝗿𝗱 𝗮𝗽𝗽𝗿𝗼𝘃𝗲𝗱 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝗶𝗻 𝘁𝗵𝗲 𝗨.𝗦. 𝗮𝗻𝗱 𝘀𝗲𝗰𝗼𝗻𝗱 𝗶𝗻 𝗶𝘁𝘀 𝗶𝗺𝗺𝘂𝗻𝗼𝗹𝗼𝗴𝘆 𝗽𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼. 𝗜𝘁 𝘁𝗿𝗲𝗮𝘁𝘀 𝘃𝗮𝗿𝗶𝗼𝘂𝘀 𝗮𝘂𝘁𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲𝘀 𝘀𝘂𝗰𝗵 𝗮𝘀 𝗿𝗵𝗲𝘂𝗺𝗮𝘁𝗼𝗶𝗱 𝗮𝗿𝘁𝗵𝗿𝗶𝘁𝗶𝘀 𝗮𝗻𝗱 𝘀𝘆𝘀𝘁𝗲𝗺𝗶𝗰 𝗷𝘂𝘃𝗲𝗻𝗶𝗹𝗲 𝗶𝗱𝗶𝗼𝗽𝗮𝘁𝗵𝗶𝗰 𝗮𝗿𝘁𝗵𝗿𝗶𝘁𝗶𝘀. Fresenius Kabi's CEO sees Tyenne® as a game-changer in the U.S. healthcare landscape, emphasizing their commitment to expanding patient access to advanced biopharmaceuticals. The company's support program aims to assist healthcare professionals and patients, ensuring broader access to treatment options. 𝗔𝗱𝗱𝗶𝘁𝗶𝗼𝗻𝗮𝗹𝗹𝘆, 𝗙𝗿𝗲𝘀𝗲𝗻𝗶𝘂𝘀 𝗞𝗮𝗯𝗶 𝗵𝗮𝘀 𝗮 𝗿𝗼𝗯𝘂𝘀𝘁 𝗽𝗶𝗽𝗲𝗹𝗶𝗻𝗲 𝗼𝗳 𝗮𝘂𝘁𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗮𝗻𝗱 𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿𝘀 𝗶𝗻 𝗹𝗮𝘁𝗲-𝘀𝘁𝗮𝗴𝗲 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁, 𝗿𝗲𝗳𝗹𝗲𝗰𝘁𝗶𝗻𝗴 𝗶𝘁𝘀 𝗱𝗲𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝘁𝗼 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻. Fresenius' overarching strategy, #FutureFresenius, focuses on becoming a leading therapy-focused company. #marketintelligence #competitiveintelligence #pharmaceutical #marketsmind #tocilizumab #freseniuskabi